18F-FDG PET imaging for treatment response assessment and management guidance in patients with skull base osteomyelitis

Awiral Saxena; Padma Subramanyam; Manjit Sarma; Bhagirath Bhad; Renjitha Bhaskaran; Shanmuga Sundaram Palaniswamy

doi:10.1097/MNM.0000000000001847

18F-FDG PET imaging for treatment response assessment and management guidance in patients with skull base osteomyelitis

Nucl Med Commun. 2024 Apr 15. doi: 10.1097/MNM.0000000000001847. Online ahead of print.

Authors

Awiral Saxena¹, Padma Subramanyam¹, Manjit Sarma¹, Bhagirath Bhad¹, Renjitha Bhaskaran², Shanmuga Sundaram Palaniswamy¹

Affiliations

¹ Department of Nuclear Medicine & Molecular Imaging and .
² Department of Biostatistics, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, India.

PMID: 38618743
DOI: 10.1097/MNM.0000000000001847

Abstract

Objective: The objective of this study is to evaluate the role of hybrid 18F-FDG PET for treatment response assessment and management guidance in patients with skull base osteomyelitis.

Materials and methods: Retrospectively, 33 patients, with at least a baseline and follow-up PET (computed tomography/MRI) scan, were included. Parameters like standardized uptake value (SUV) max, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) (initial, follow-up, percentage change) were analysed and outcomes based on 18F-FDG PET reports were classified into resolution (a), partial response (b), progression (c) and stable disease (d). The clinical course and response on anatomical imaging were also compared with 18F-FDG PET.

Results: There was mild correlation between initial SUV with ESR (0.338) and CRP (0.384). Moderate correlation was seen between follow-up SUV and CRP (0.619), percentage change in SUV max (PC SUV) with percentage change in ESR (0.456) and CRP (0.668). Mean PC SUV was 70% (a), 35% (b), -40% (c) and -18% (d), respectively. 48% (16/33) (resolution, progression, stable disease) patients had clear management change with 18F-FDG PET with either escalation or stopping of antibiotics/antifungals. Management decision in partial response group (52%, 17/33) was taken clinically. On retrospective PC SUV analysis, treatment continuation group (8 patients) showed 20% decrease, whereas the group that was only monitored further (9 patients) had 48% reduction in SUV.

Conclusion: 18F-FDG PET showed a moderate association with clinical markers used in follow-up of patients with skull base osteomyelitis and is a reliable investigation for assessment of disease status. This can be used as a guide along with clinical evaluation for de-escalation of treatment.